The average survival time of lung adenocarcinoma with advanced bone metastasis is about 1 year, which can be prolonged to a certain extent if targeted drugs and immunologic drugs are available. Bone metastasis is a more common manifestation of lung cancer in advanced stage, and the survival time after bone metastasis of lung cancer is determined by different pathological types and different gene mutation status. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer, and the survival time is as follows: 1. Small cell lung cancer: if bone metastasis occurs in small cell lung cancer, the average survival time is in 1 year according to the current statistics; 2. non-small cell lung cancer: if patients with squamous lung cancer only do simple chemotherapy, the average survival time may be 1 year. However, if immunotherapy is added, the average survival time can be about 1.5 years. If adenocarcinoma has EGFR mutation, the survival time can reach 2-3 years through oral targeted drugs, and if it has ALK mutation, the survival time can reach 4-6 years or even longer. When bone metastasis occurs in the advanced stage of lung adenocarcinoma, firstly, radiotherapy, targeted drugs or immunotherapy should be carried out according to the primary lesion of lung adenocarcinoma to control the cause of the disease effectively, and at the same time, pain-relieving drugs can be used for the metastatic site, and zoledronic acid can be used to inhibit bone resorption to relieve the symptom. For people with bone metastasis in advanced stage of lung adenocarcinoma, it is recommended to go to the hospital for regular review and receive anti-cancer treatment under the guidance of doctors.